Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein {alpha}

Conclusion: [68Ga]Ga-DOTA-4AH29 and [131I]I-GMIB-4AH29 enable precise FAP-positive tumor detection in mice. Therapeutic [225Ac]Ac-DOTA-4AH29 and [131I]I-GMIB-4AH29 exhibit strong and sustained tumor targeting, resulting in dose-dependent therapeutic effects in FAP-positive tumor-bearing mice, albeit with kidney toxicity observed later for [225Ac]Ac-DOTA-4AH29. This study confirms the potential of radiolabeled sdAb 4AH29 as a radiotheranostic agent for FAP-positive cancers, warranting clinical evaluation.

Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Dekempeneer, Y., Massa, S., Santens, F., Navarro, L., Berdal, M., Lucero, M. M., Pombo Antunes, A. R., Lahoutte, T., Van Ginderachter, J. A., Devoogdt, N., DHuyvetter, M. Tags: Basic Science Investigations Source Type: research